{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:01:58Z","timestamp":1791216118028,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.critrevonc.2014.12.017","type":"journal-article","created":{"date-parts":[[2015,1,22]],"date-time":"2015-01-22T14:09:04Z","timestamp":1421935744000},"page":"164-178","source":"Crossref","is-referenced-by-count":12,"title":["Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example"],"prefix":"10.1016","volume":"94","author":[{"given":"U.","family":"Rochau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Qerimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kurzthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kluibenschaedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2014.12.017_bib0285","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0290","series-title":"54th Annual Meeting of the American Society of Hematology","article-title":"Continued improvement in survival in multiple myeloma and the impact of novel agents","year":"2012"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.12.017_bib0295","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10198-003-0205-2","article-title":"When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial]","volume":"4","author":"Siebert","year":"2003","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0300","unstructured":"Phillips C. What is cost\u2013effectiveness? Health economics 2009. What is...? series. 2nd ed., p. 1\u20138 [Epub]"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0305","unstructured":"University of York, Centre for Reviews and Dissemination. Available from: http:\/\/www.crd.york.ac.uk\/CRDWeb\/ [last accessed 02.13.14]; 2013."},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0310","unstructured":"Tufts Medical Center, CEA \u2013 Cost\u2013effectiveness Analysis Registry. Available from: https:\/\/research.tufts-nemc.org\/cear4\/ [last accessed 02.13.14]."},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0315","unstructured":"National Center for Biotechnology Information, U.S. National Library of Medicine. PubMed. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/ [last accessed 02.13.14]."},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0320","unstructured":"U.S. Department of Labor, Bureau of Labor Statistics, Consumer Price Index. All Urban Consumers \u2013 (CPI-U). Available from: ftp:\/\/ftp.bls.gov\/pub\/special.requests\/cpi\/cpiai.txt [last accessed 06.20.13]; 2013."},{"issue":"5","key":"10.1016\/j.critrevonc.2014.12.017_bib0325","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices \u2013 overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"32","author":"Caro","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0330","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 [Plus Editorial]","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0335","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0340","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2","volume":"32","author":"Roberts","year":"2012","journal-title":"Med Decis Mak"},{"issue":"5","key":"10.1016\/j.critrevonc.2014.12.017_bib0345","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Mak"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.12.017_bib0350","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) \u2013 explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0355","series-title":"Decision making in health and medicine: integrating evidence and values","author":"Hunink","year":"2001"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.12.017_bib0360","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/10428190309178811","article-title":"Cost\u2013effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma","volume":"44","author":"Kouroukis","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.12.017_bib0365","first-page":"1475","article-title":"Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost\u2013effectiveness evaluation","volume":"5","author":"Trippoli","year":"1998","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.12.017_bib0370","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2010.01526.x","article-title":"The cost\u2013effectiveness of bortezomib in relapsed\/refractory multiple myeloma: Swedish perspective","volume":"85","author":"Hornberger","year":"2010","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.12.017_bib0375","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3747\/co.19.1004","article-title":"Cost\u2013effectiveness of zoledronic acid compared with clodronate in multiple myeloma","volume":"19","author":"Delea","year":"2012","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.12.017_bib0380","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3111\/13696998.2011.653511","article-title":"Cost\u2013effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective","volume":"15","author":"Delea","year":"2012","journal-title":"J Med Econ"},{"issue":"41","key":"10.1016\/j.critrevonc.2014.12.017_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15410","article-title":"The clinical effectiveness and cost\u2013effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.12.017_bib0390","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/03007995.2010.543125","article-title":"Modelled cost\u2013effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney","volume":"27","author":"Grima","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.12.017_bib0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","volume":"18","author":"Garrison","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0400","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/0272989X12455462","article-title":"Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4","volume":"32","author":"Karnon","year":"2012","journal-title":"Med Decis Mak"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.12.017_bib0405","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10198-012-0395-6","article-title":"Lenalidomide for multiple myeloma: cost\u2013effectiveness in patients with one prior therapy in England and Wales","volume":"14","author":"Brown","year":"2013","journal-title":"Eur J Health Econ"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.12.017_bib0410","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3111\/13696998.2011.611841","article-title":"Cost\u2013effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib","volume":"14","author":"Moller","year":"2011","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.12.017_bib0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices \u2013 modeling studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.critrevonc.2014.12.017_bib0420","first-page":"52","article-title":"Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma","volume":"17","author":"Mehta","year":"2004","journal-title":"Manag Care Interface"},{"issue":"6","key":"10.1016\/j.critrevonc.2014.12.017_bib0425","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2165\/00019053-199507060-00004","article-title":"Multi-attribute health status classification systems, Health Utilities Index","volume":"7","author":"Feeny","year":"1995","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.critrevonc.2014.12.017_bib0430","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0435","series-title":"Decision making in health care","first-page":"289","article-title":"Assessing patients\u2019 preferences","author":"Stiggelbout","year":"2000"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.12.017_bib0440","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0445","series-title":"Guide to the methods of technology appraisal, London, United Kingdom","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0450","series-title":"Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3), Publications Approval Number: P3-4706, Canberra, Australia","author":"Australian Government, Department of Health and Ageing","year":"2008"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0455","series-title":"Appropriate perspectives for health care decisions. CHE research paper 54","author":"Claxton","year":"2010"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0460","series-title":"French guidelines for the economic evaluation of health care technologies, Paris, France","author":"College Des Economistes De La Sante","year":"2004"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0465","series-title":"Utv\u00e4rdering av metoder i h\u00e4lso-och sjukv\u00e5rden. En, handbok, Stockholm, Sweden","author":"Statens beredning f\u00f6r medicinsk, utv\u00e4rdering","year":"2013"},{"issue":"13","key":"10.1016\/j.critrevonc.2014.12.017_bib0470","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJM197703312961304","article-title":"Foundations of cost\u2013effectiveness analysis for health and medical practices","volume":"296","author":"Weinstein","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0475","series-title":"Economic evaluation in health care: merging theory with practice","author":"Drummond","year":"2001"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0480","series-title":"Cost\u2013effectiveness in health and medicine","first-page":"1","author":"Gold","year":"1996"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0485","series-title":"Do existing cost\u2013effectiveness thresholds adequately support decision making for PCM? A review of international practice 14th Biennal SMDM European Meeting, June 10\u201312; 25.07.2012\u201327.07.2012; Oslo, Norway","year":"2012"},{"issue":"4","key":"10.1016\/j.critrevonc.2014.12.017_bib0490","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1524-4733.2007.00298.x","article-title":"The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond","volume":"11","author":"Rocchi","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0495","series-title":"Making choices in health: WHO guide to cost\u2013effectiveness analysis","author":"Edejer","year":"2003"},{"issue":"9\u201310","key":"10.1016\/j.critrevonc.2014.12.017_bib0500","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.zefq.2013.10.020","article-title":"When is enough evidence enough? Using systematic decision analysis and value-of-information analysis to determine the need for further evidence","volume":"107","author":"Siebert","year":"2013","journal-title":"Z. Evid. Fortbild. Qual. Gesundheitswes."},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0505","series-title":"United Kingdom (England and Wales) \u2013 reimbursement and pricing approval process","author":"International Society for Pharmacoeconomics and Outcomes Research (ISPOR)","year":"2008"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0510","series-title":"Bortezomib and thalidomide for the first-line treatment of multiple myeloma, London, United Kingdom","author":"National Institute for Health and Care Excellence (NICE)","year":"2011"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0515","series-title":"Multiple myeloma (first line) \u2013 bortezomib and thalidomide (TA228), London, United Kingdom","author":"National Institute for Health and Care Excellence (NICE)","year":"2011"},{"issue":"1","key":"10.1016\/j.critrevonc.2014.12.017_bib0520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0266462301104058","article-title":"Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease","volume":"17","author":"Claxton","year":"2001","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"10.1016\/j.critrevonc.2014.12.017_bib0525","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/0272989X04263162","article-title":"Expected value of sample information calculations in medical decision modeling","volume":"24","author":"Ades","year":"2004","journal-title":"Med Decis Mak: Int J Soc Med Decis Mak"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0530","series-title":"AWMF-Regelwerk Leitlinien","author":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)","year":"2012"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0535","series-title":"Final recommendation statement \u2013 breast cancer: screening","author":"U.S. Preventive Services Task Force","year":"2014"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0540","series-title":"Empirical model-building and response surfaces","author":"Box","year":"1987"},{"key":"10.1016\/j.critrevonc.2014.12.017_bib0545","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jval.2014.01.003","article-title":"Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force Report","volume":"17","author":"Caro","year":"2014","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.critrevonc.2014.12.017_bib0550","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2014.12.017_bib0555","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices \u2013 overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"32","author":"Caro","year":"2012","journal-title":"Med Decis Mak: Int J Soc Med Decis Mak"},{"issue":"3","key":"10.1016\/j.critrevonc.2014.12.017_bib0560","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd2269","article-title":"Multiple myeloma therapies","volume":"6","author":"Strobeck","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814002376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842814002376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:31:01Z","timestamp":1566261061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842814002376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1040842814002376"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2014.12.017","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}